Literature DB >> 33517884

Generation and identification of a conditional knockout allele for the PSMD11 gene in mice.

Linlin Zhao1, Jinming Zhao1, Yingying Zhang1, Lele Wang2, Longyan Zuo3, Airu Niu4, Wei Zhang5, Xia Xue6, Suhong Zhao5, Chao Sun1, Kailin Li1, Jue Wang1, Zhimin Bian7, Xiaogang Zhao8, Dieter Saur9, Barbara Seidler9, Chuanxin Wang2, Tonggang Qi10.   

Abstract

BACKGROUND: Our previous study have shown that the PSMD11 protein was an important survival factor for cancer cells except for its key role in regulation of assembly and activity of the 26S proteasome. To further investigate the role of PSMD11 in carcinogenesis, we constructed a conditional exon 5 floxed allele of PSMD11 (PSMD11flx) in mice.
RESULTS: It was found that homozygous PSMD11 flx/flx mice showed normal and exhibited a normal life span and fertility, and showed roughly equivalent expression of PSMD11 in various tissues, suggesting that the floxed allele maintained the wild-type function. Cre recombinase could induce efficient knockout of the floxed PSMD11 allele both in vitro and in vivo. Mice with constitutive single allele deletion of PSMD11 derived from intercrossing between PSMD11flx/flx and CMV-Cre mice were all viable and fertile, and showed apparent growth retardation, suggesting that PSMD11 played a significant role in the development of mice pre- or postnatally. No whole-body PSMD11 deficient embryos (PSMD11-/-) were identified in E7.5-8.5 embryos in uteros, indicating that double allele knockout of PSMD11 leads to early embryonic lethality. To avoid embryonic lethality produced by whole-body PSMD11 deletion, we further developed conditional PSMD11 global knockout mice with genotype Flp;FSF-R26CAG - CreERT2/+; PSMD11 flx/flx, and demonstrated that PSMD11 could be depleted in a temporal and tissue-specific manner. Meanwhile, it was found that depletion of PSMD11 could induce massive apoptosis in MEFs.
CONCLUSIONS: In summary, our data demonstrated that we have successfully generated a conditional knockout allele of PSMD11 in mice, and found that PSMD11 played a key role in early and postnatal development in mice, the PSMD11 flx/flx mice will be an invaluable tool to explore the functions of PSMD11 in development and diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33517884      PMCID: PMC7849139          DOI: 10.1186/s12861-020-00233-1

Source DB:  PubMed          Journal:  BMC Dev Biol        ISSN: 1471-213X            Impact factor:   1.978


  33 in total

1.  High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP.

Authors:  C I Rodríguez; F Buchholz; J Galloway; R Sequerra; J Kasper; R Ayala; A F Stewart; S M Dymecki
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

Review 2.  RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer.

Authors:  M R Culbertson
Journal:  Trends Genet       Date:  1999-02       Impact factor: 11.639

3.  Functional analysis of Rpn6p, a lid component of the 26 S proteasome, using temperature-sensitive rpn6 mutants of the yeast Saccharomyces cerevisiae.

Authors:  Erika Isono; Naoko Saito; Naoko Kamata; Yasushi Saeki; Akio Toh-E
Journal:  J Biol Chem       Date:  2004-12-15       Impact factor: 5.157

4.  Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.

Authors:  Tonggang Qi; Wei Zhang; Yun Luan; Feng Kong; Dawei Xu; Guanghui Cheng; Yunshan Wang
Journal:  Mol Cell Proteomics       Date:  2013-10-08       Impact factor: 5.911

Review 5.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

6.  Molecular cloning and expression of subunit 9 of the 26S proteasome.

Authors:  L Hoffman; M Rechsteiner
Journal:  FEBS Lett       Date:  1997-03-10       Impact factor: 4.124

7.  A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

Authors:  David P Ryan; Bert H O'Neil; Jeffrey G Supko; Carlo M Rocha Lima; E Claire Dees; Leonard J Appleman; Jeffrey Clark; Phinos Fidias; Robert Z Orlowski; Oscar Kashala; Joseph P Eder; James C Cusack
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

Review 8.  Proteasome inhibitors: structure and function.

Authors:  Ana T Nunes; Christina M Annunziata
Journal:  Semin Oncol       Date:  2018-04-12       Impact factor: 4.929

9.  A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

Authors:  Ji Luo; Michael J Emanuele; Danan Li; Chad J Creighton; Michael R Schlabach; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582

10.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Authors:  Michael Steckel; Miriam Molina-Arcas; Britta Weigelt; Michaela Marani; Patricia H Warne; Hanna Kuznetsov; Gavin Kelly; Becky Saunders; Michael Howell; Julian Downward; David C Hancock
Journal:  Cell Res       Date:  2012-05-22       Impact factor: 25.617

View more
  1 in total

Review 1.  Protein clearance strategies for disease intervention.

Authors:  Franziska Hommen; Saygın Bilican; David Vilchez
Journal:  J Neural Transm (Vienna)       Date:  2021-10-23       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.